Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

Completed · Phase 4

Conditions studied: Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity

In brief

Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related toxicities. Therefore, the investigators hypothesize that by transitioning patients from tacrolimus immediate release to Envarsus ®, the peak-dose effect will be eliminated or attenuated, leading to a significant decrease in neurocognitive toxicities in the older patient population.

Key facts

Study ID
NCT03461445
Run by
University of California, Davis
People needed
64
Starts
2018-04-01
Expected to finish
2023-07-31
Last updated by the study team
2025-04-08

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.